Skip to main content

Mismatch Repair Deficiency clinical trials at UCSD

2 in progress, 1 open to eligible people

Showing trials for
  • STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors

    open to eligible people ages 18 years and up

    This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of STK-012 as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors.

    La Jolla, California and other locations

  • RP1 Monotherapy and RP1 in Combination With Nivolumab

    Sorry, not currently recruiting here

    RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

    La Jolla, California and other locations

Last updated: